Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00788073 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome
A Phase 2 study, sponsored by Seaside Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT00788073: Completed Phase 2 study, sponsored by Seaside Therapeutics.
NCT00788073 is a Phase 2 study that has completed, run by Seaside Therapeutics. The registered enrollment target is 63 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00788073, a Phase 2 study, has completed, sponsored by Seaside Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
The study objective is to explore the efficacy, safety and tolerability of STX209 for treatment of irritability in subjects with FSX. We hypothesize that STX209 will improve irritability and other typical problem behaviors associated with fragile X syndrome. We also hypothesize that STX209 will be safe and well tolerated.
Interventions
- DRUG Placebo
- DRUG STX209
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2008-11 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00788073
The ClinicalTrials.gov registry entry for NCT00788073 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seaside Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00788073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00788073 about?
NCT00788073 is a clinical study titled "Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome". The study objective is to explore the efficacy, safety and tolerability of STX209 for treatment of irritability in subjects with FSX. We hypothesize that STX209 will improve irritability and other typical problem behaviors associated with fragile X syndrome. We also hypothesize that STX209 will be s...
What is the current status of trial NCT00788073?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2008-11. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00788073?
The interventions under investigation include: Placebo (DRUG), STX209 (DRUG).
Who is sponsoring clinical trial NCT00788073?
This trial is sponsored by Seaside Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.